Entasis Therapeutics Holdings Inc.
SEC CIK 1724344 · [ETTX] · last insider filing 2022-07-13
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Innoviva Strategic Opportunities LLC | Director | filed 2021 - 2022 |
| Hastings David C | Director | filed 2018 - 2022 |
| Meek David D. | Director | filed 2019 - 2022 |
| Mayer Howard | Director | filed 2019 - 2022 |
| Perros Manoussos | Director · See Remarks | filed 2018 - 2022 |
| Berger Heather A. | Director | filed 2018 - 2022 |
| Topper James N | Director | filed 2018 - 2020 |
| Galakatos Nicholas | Director | filed 2018 - 2019 |
| Norden Gregory | Director | filed 2018 - 2019 |
| Preston Heather | Director | filed 2018 - 2019 |
| Staples Andrew J. | Director | filed 2018 - 2018 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Keiley Elizabeth M | General Counsel | filed 2019 - 2022 |
| Tommasi Rubin | Chief Scientific Officer | filed 2018 - 2022 |
| Mueller John Patrick | Chief Development Officer | filed 2018 - 2022 |
| Altarac David | Chief Medical Officer | filed 2019 - 2022 |
| Ronsheim Matthew | See Remarks | filed 2020 - 2022 |
| Triola Anna Diaz | Chief Commercial Officer | filed 2021 - 2022 |
| Wagner Kristie Ann | VP, Principal Fin & Acct Off | filed 2022 - 2022 |
| Gutch Michael | See Remarks | filed 2018 - 2022 |
| Kimble Eric Wilson | Chief Commercial Officer | filed 2019 - 2020 |
| Isaacs Robin | Chief Medical Officer | filed 2018 - 2019 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.